{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Colorectal&page=35", "query": { "condition": "Carcinoma, Colorectal", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 2788, "total_pages": 279, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Colorectal&page=36&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Colorectal&page=34&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T00:11:49.846Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07262619", "title": "EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "MSI-H or dMMR Advanced Solid Tumors", "MSI-H/dMMR Gastric Cancer", "MSI-H/dMMR Colorectal Cancer", "MSI-H/dMMR Gastroesophageal-junction Cancer", "Endometrial Cancer", "Mismatch Repair Deficient or MSI-High Solid Tumors" ], "interventions": [ { "name": "EIK1005", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA® )", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-01-20", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-16T00:11:49.846Z", "location_count": 10, "location_summary": "Los Angeles, California • Doral, Florida • Hialeah, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Tamarac", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07262619" }, { "nct_id": "NCT00873275", "title": "Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "ursodiol", "type": "DRUG" }, { "name": "RNA analysis", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "positron emission tomography (PET)", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2009-03-11", "completion_date": "2025-02-26", "has_results": false, "last_update_posted_date": "2025-06-22", "last_synced_at": "2026-10-16T00:11:49.846Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00873275" }, { "nct_id": "NCT03317119", "title": "Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colon Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Rectal Carcinoma", "RAS Family Gene Mutation", "Stage III Colon Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Rectal Cancer AJCC v7", "Stage IIIA Colon Cancer AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIA Rectal Cancer AJCC v7", "Stage IIIB Colon Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIB Rectal Cancer AJCC v7", "Stage IIIC Colon Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IIIC Rectal Cancer AJCC v7", "Stage IV Colon Cancer AJCC v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Rectal Cancer AJCC v7", "Stage IVA Colon Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVA Rectal Cancer AJCC v7", "Stage IVB Colon Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7", "Stage IVB Rectal Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2018-04-11", "completion_date": "2023-07-14", "has_results": false, "last_update_posted_date": "2024-04-08", "last_synced_at": "2026-10-16T00:11:49.846Z", "location_count": 8, "location_summary": "Corona, California • Duarte, California • Lancaster, California + 5 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03317119" }, { "nct_id": "NCT04731467", "title": "A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non Small Cell Lung Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Papillary Thyroid Cancer", "Melanoma", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "CM-24 and Nivolumab - Dose Escalation", "type": "DRUG" }, { "name": "CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion", "type": "DRUG" }, { "name": "CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion", "type": "DRUG" }, { "name": "Nivolumab, Nab paclitaxel and Gemcitabine - Expansion", "type": "DRUG" }, { "name": "Nivolumab and Nal-IRI/5-FU/LV - Expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Famewave Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2021-03-19", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-16T00:11:49.846Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04731467" }, { "nct_id": "NCT06937177", "title": "Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer Weight Loss" ], "interventions": [ { "name": "TCMCB07", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endevica Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-04-28", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-16T00:11:49.846Z", "location_count": 25, "location_summary": "Tucson, Arizona • Los Angeles, California • Santa Monica, California + 22 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06937177" }, { "nct_id": "NCT06778863", "title": "A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Metastatic Solid Tumor", "Colorectal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Lung Cancer", "Ovarian Cancer", "Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Prostate Cancer", "Bladder Cancer" ], "interventions": [ { "name": "CLSP-1025", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clasp Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2025-02-28", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-16T00:11:49.846Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06778863" }, { "nct_id": "NCT06973564", "title": "JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "JAB-23E73", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobio Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2025-05-29", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-10-16T00:11:49.846Z", "location_count": 4, "location_summary": "Rochester, Minnesota • St Louis, Missouri • Cleveland, Ohio + 1 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06973564" }, { "nct_id": "NCT01451632", "title": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Squamous Cell Head and Neck Cancer", "Non-small Cell Lung Cancer", "Triple Negative Breast Cancer", "Other Tumors With EGFR Dependence" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2011-10", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-09-08", "last_synced_at": "2026-10-16T00:11:49.846Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01451632" }, { "nct_id": "NCT02005614", "title": "A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma", "Renal Cell Carcinoma", "Sarcoma", "Breast Cancer", "Lung Cancer", "Colorectal Cancer", "Gastrointestinal Cancers", "Brain Metastases" ], "interventions": [ { "name": "Gamma Knife Radiosurgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2013-11", "completion_date": "2018-08", "has_results": false, "last_update_posted_date": "2019-07-01", "last_synced_at": "2026-10-16T00:11:49.846Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02005614" }, { "nct_id": "NCT05989724", "title": "A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Breast Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "SON-DP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Qurgen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2023-09-19", "completion_date": "2026-03", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-16T00:11:49.846Z", "location_count": 5, "location_summary": "Gilbert, Arizona • Detroit, Michigan • Huntersville, North Carolina + 2 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05989724" } ] }